RS2 Healthcare Partners
RS2 Healthcare Partners is a Boston-based private equity firm (founded 1989, rebranded 2026) that invests $3–15M EBITDA growth and control capital in lower-middle-market healthcare companies across North America, managing approximately $1.1 billion in equity capital across six funds.
- Company typePrivate
- Founded1989
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What RS2 Healthcare Partners does
RS2 Healthcare Partners (formerly Riverside Partners) is a Boston-based private equity firm founded in 1989 that invests in lower-middle-market companies with $3–15 million in EBITDA and $20–200 million in revenue, primarily in healthcare and, historically, technology. Following a May 2026 rebrand, the firm has formalized an exclusive focus on healthcare investing across subsectors including healthcare IT, medical products and equipment, provider and payer services, contract manufacturing, lab products and services, and pharma services. The firm operates a traditional fund-based private equity model, managing approximately $1.1 billion of equity capital across six funds, with Riverside Fund V (2012) having raised $561 million.
The firm's core offering is control and growth-equity capital paired with operational support from a team of former operators and consultants. Portfolio company examples include Revecore (revenue integrity for ~1,200 hospitals), Loftware (enterprise labeling software generating approximately $125 million in revenue and serving over 10,000 customers across 100+ countries), Sequoia and Syner-G (life sciences consulting and CMC/regulatory services, now combined), UnisLink (revenue cycle and population health management), Net32 (dental supplies eCommerce), HealthDrive, and Convergence Networks (managed IT/cybersecurity). RS2 earns revenue through management fees on committed and invested capital from institutional limited partners and through carried interest on successful portfolio company exits.
RS2 pursues an active buy-and-build value creation model, with portfolio companies executing add-on acquisitions (UnisLink's 2023 acquisitions of AQREVA, Doctors' Resource Specialists, and HST; Revecore's acquisitions of Kemberton and Cura; Sequoia/Syner-G combinations). Realizations have included the 2026 Loftware continuation vehicle with AKKR Strategic Capital, the 2023 partial sale of Loftware to Accel-KKR, the 2022 Revecore partial exit to GrowthCurve Capital, and historical exits of Vocollect ($190M to Intermec), IZI Medical Products ($93M to Landauer), BioAgilytix (to Cobepa), and Eliassen Group (to Stone Point Capital). The firm has been named to the Inc. Founder-Friendly Investors list for four consecutive years (2022–2025).
RS2 Healthcare Partners firmographics
Firmographics- Name
- RS2 Healthcare Partners
- Legal name
- Riverside Partners, LLC
- Website
- https://rs2healthcare.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RS2 Healthcare Partners is a Boston-based private equity firm (founded 1989, rebranded 2026) that invests $3–15M EBITDA growth and control capital in lower-middle-market healthcare companies across North America, managing approximately $1.1 billion in equity capital across six funds.
- Ownership category
- akta.pro rank
RS2 Healthcare Partners industry classification
Industry- Product category
- Private Equity Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Business Services (B2B) Growth Equity (FSANACAD)
- akta.pro secondary industries
- LP Secondaries — Growth Equity Funds (FSAHALAC), Secondary Fund Stakes (GP/Manager Stakes in Secondary GPs) (FSANAFAD)
Keywords
Where RS2 Healthcare Partners is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RS2 Healthcare Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management Fees: Generates management fees from managing private equity funds for institutional investors
- Carried Interest: Earns performance-based carried interest from successful portfolio company exits
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
RS2 Healthcare Partners product offering
Product offeringCore offering
RS2 Healthcare Partners is a Boston-based private equity firm that makes control investments and growth equity investments in lower middle market healthcare companies with $3-15M EBITDA across North America. The firm manages approximately $1.1 billion of equity capital from institutional limited partners and provides portfolio companies with capital, sector expertise, and an advisory network to accelerate growth alongside management teams.
Product overview
RS2 Healthcare Partners (formerly Riverside Partners) is a single private equity firm offering. The firm is not structured as a platform with modules but rather provides investment capital, industry expertise, and operational support to portfolio companies. The firm targets companies with $3-15 million EBITDA in healthcare and technology sectors across North America.
Differentiator
Problem solved
Functional benefit
Products and services
- Riverside Fund V, L.P. Riverside Fund V, L.P. is a $561 million private equity fund raised in 2012 that invests growth equity and makes control investments in lower middle market healthcare and technology companies across North America. The fund is offered to institutional limited partners as a commingled investment vehicle.
- RS2 Healthcare Partners Sixth Fund (Current Investing Fund) The firm's current sixth private equity fund, representing approximately $1.1 billion of equity capital under management, invests growth equity and makes control investments in lower middle market healthcare companies with $3-15M EBITDA across North America. The fund is offered to institutional limited partners as a commingled investment vehicle.
- Loftware Single-Asset Continuation Vehicle The Loftware Single-Asset Continuation Vehicle is a discrete investment vehicle closed in 2026 with AKKR Strategic Capital as lead investor, providing dedicated growth capital to Loftware while enabling RS2 Healthcare Partners to deploy capital toward new platform investments.
Quantifiable outcome
- Multiple successful exits including Vocollect ($190M to Intermec), IZI Medical Products ($93M to Landauer), IPA to Roper Industries, BioAgilytix to Cobepa, Eliassen Group to Stone Point Capital
- +1 more outcomes
Companies that use RS2 Healthcare Partners
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
RS2 Healthcare Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RS2 Healthcare Partners partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
RS2 Healthcare Partners competitors and assessment
Company assessmentDirect peers
- Audax Private Equity: Boston-based lower middle market PE firm with a similar focus on healthcare and technology companies in the $5-50M EBITDA range. Both firms pursue control investments with management rollover and are comparable in scale and strategy.
- Webster Equity Partners: Healthcare-services focused lower middle market PE firm based in Boston. Webster's exclusive healthcare focus and similar deal-size range makes it the most direct competitor; two of RS2's recent hires (Alicia Alexander, Joshua Griffin) came from Webster.
- Enhanced Healthcare Partners: Healthcare-only middle market PE firm making control and growth equity investments. Patrick Furlong, an RS2 Partner, previously worked at Enhanced Healthcare, indicating a direct talent and strategy overlap.
- Excellere Partners: Lower middle market PE firm with healthcare and technology verticals, headquartered in Denver. Similar investment criteria and sector focus to RS2 makes it a direct strategic peer.
- Flexpoint Ford: Healthcare and financial services focused PE firm. Patrick Furlong joined RS2 from Flexpoint Ford, indicating direct talent and strategy overlap, with comparable lower middle market healthcare investing approach.
- Amulet Capital Partners: Healthcare-only middle market PE firm with comparable investment size and strategy, making control investments in healthcare services, medical products, and pharma services businesses.
- Cressey & Company: Healthcare-focused PE firm making growth equity investments in lower middle market healthcare services and technology companies. Comparable sector specialization and investment size range.
- Varsity Healthcare Partners: Lower middle market healthcare services PE firm with similar focus on control investments and management partnerships. Closely comparable in deal size, sector focus, and partnership approach.
Broad incumbents
- Linden Capital Partners: Healthcare-focused PE firm that is significantly larger than RS2 and concentrates on buyouts of healthcare services and pharma services businesses. Comparable by sector focus but operates at higher end of middle market.
- Avista Capital Partners: Healthcare-focused middle market PE firm with substantially larger AUM. Comparable healthcare sector focus and growth equity strategy but generally invests in larger platforms than RS2's lower middle market sweet spot.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
RS2 Healthcare Partners social profiles
Digital presenceRS2 Healthcare Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
RS2 Healthcare Partners leadership team
Management profileNumber of profiles
Profiles8 records
RS2 Healthcare Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RS2 Healthcare Partners M&A and investment
M&A and investmentM&A25 records
Investments15 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RS2 Healthcare Partners
What does RS2 Healthcare Partners do?
RS2 Healthcare Partners is a Boston-based private equity firm that makes control investments and growth equity investments in lower middle market healthcare companies with $3-15M EBITDA across North America. The firm manages approximately $1.1 billion of equity capital from institutional limited partners and provides portfolio companies with capital, sector expertise, and an advisory network to accelerate growth alongside management teams.
Is RS2 Healthcare Partners a public or private company?
RS2 Healthcare Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RS2 Healthcare Partners founded?
RS2 Healthcare Partners was founded in 1989. It employs 11 to 50 people.
Where is RS2 Healthcare Partners based?
RS2 Healthcare Partners is headquartered in Boston, United States, in the North America region.
How does RS2 Healthcare Partners make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest.
Who are RS2 Healthcare Partners's main competitors?
Direct peers on record are Audax Private Equity, Webster Equity Partners, Enhanced Healthcare Partners, Excellere Partners, Flexpoint Ford, Amulet Capital Partners, Cressey & Company and Varsity Healthcare Partners. Broad incumbents are Linden Capital Partners and Avista Capital Partners.
Does RS2 Healthcare Partners have an API?
No public API is recorded for RS2 Healthcare Partners.
What industry is RS2 Healthcare Partners in?
RS2 Healthcare Partners's product category is Private Equity Investment Management. Its primary akta.pro industry code is FSANACAD, Business Services (B2B) Growth Equity, with a secondary code of FSAHALAC, LP Secondaries — Growth Equity Funds. Its NAICS code is 523940 and its SIC code is 6282.